Annotation Detail

Information
Associated Genes
CDK4
Associated Variants
CDK4 AMPLIFICATION ( ENST00000257904.11 )
CDK4 AMPLIFICATION ( ENST00000257904.11 )
Associated Disease
liposarcoma
Source Database
CIViC Evidence
Description
In a phase 2 clinical trial, NCT01209598, 30 patients with CDK4-amplified and RB-expressing well differentiated and dedifferentiated liposarcomas (WDLS/DDLS) were treated with a selective CDK 4/6 inhibitor, PD0332991. Treatment with PD0332991 was associated with favorable progression free survival rates (66% PFS rate, primary end point being greater than 40%) suggesting that CDK4 amplification is predictive of sensitivity to CDK4 inhibitor therapy.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1366
Gene URL
https://civic.genome.wustl.edu/links/genes/13
Variant URL
https://civic.genome.wustl.edu/links/variants/553
Rating
3
Evidence Type
Predictive
Disease
Liposarcoma
Evidence Direction
Supports
Drug
Palbociclib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
23569312
Drugs
Drug NameSensitivitySupported
PalbociclibSensitivitytrue